Showing results (121-130 of 366) with videos related to
Sort By:
Pageof 37
Plos Computational Biology|December 25, 2015
Distinctive Behaviors of Druggable Proteins in Cellular NetworksCostas Mitsopoulos, Amanda C Schierz, Paul Workman, et al.International Journal of Cardiology|March 18, 2005
Depressive symptoms and treatment after acute coronary syndromeJeffrey J Ellis, Kim A Eagle, Eva M Kline-Rogers, et al.Current Medical Research and Opinion|August 9, 2005
Validation of the EQ-5D in patients with a history of acute coronary syndromeJeffrey J Ellis, Kim A Eagle, Eva M Kline-Rogers, et al.Cardiology|August 17, 2005
Perceived work performance of patients who experienced an acute coronary syndrome eventJeffrey J Ellis, Kim A Eagle, Eva M Kline-Rogers, et al.Pharmacotherapy|September 29, 2011
Mapping geographic areas of high and low drug adherence in patients prescribed continuing treatment for acute coronary syndrome after dischargeCuong Hoang, Giselle Kolenic, Eva Kline-Rogers, et al.Cellular Signalling|January 14, 2018
Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signallingMichael D Bright, Paul A Clarke, Paul Workman, et al.Cell|February 11, 2017
How Much Longer Will We Put Up With $100,000 Cancer Drugs?Paul Workman, Giulio F Draetta, Jan H M Schellens, et al.Journal of Biomolecular Screening|July 10, 2012
Small-molecule inhibitors of the protein methyltransferase SET7/9 identified in a high-throughput screenNicola-Jane Francis, Martin Rowlands, Paul Workman, et al.JAMA Ophthalmology|March 5, 2026
Intracameral Cefuroxime Use in Cataract Surgery After Penicillin Allergy ReclassificationKarthik Reddy, Paul Workman, Greg Eschenauer, et al.Cancer Research|January 20, 2004
The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathwaySteven R Whittaker, Mike I Walton, Michelle D Garrett, et al.Pageof 37